Burton, C., Smith, P., Vaughan-Hudson, G., Qian, W., Hoskin, P., Cunningham, D., Hancock, B., Linch, D. (2005) Comparison of CHOP versus CIOP in good prognosis younger patients with histologically aggressive non-Hodgkin lymphoma. BRITISH JOURNAL OF HAEMATOLOGY, 130 (4). pp. 536-541. ISSN 0007-1048

Full text not available from this repository.

Abstract

Comparison of CHOP versus CIOP in good prognosis younger patients with histologically aggressive non-Hodgkin lymphoma CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone) has been the standard chemotherapy regimen used for diffuse large cell lymphomas for over 30 years. Idarubicin is a 4-demethoxy-anthracycline analogue of daunorubicin that has proven activity in non-Hodgkin lymphoma, and has been reported to cause less cardiotoxicity. We therefore initiated a randomised trial of standard dose CHOP versus CIOP (cyclophosphamide, idarubicin, vincristine and prednisolone), in which doxorubicin 50 mg/m(2) was substituted by idarubicin 10 mg/m(2), a dose thought to have equivalent anti-lymphoma activity. This trial was closed prematurely after 211 patients had completed therapy when a lower complete remission (CR) rate was noted in the CIOP arm. The formal results with long-term follow up are now reported. Overall response rate was 84% in the CHOP arm and 78% in the CIOP arm, CR rates were 70% and 52% respectively in all patients (P = 0.013) and 73% and 52% respectively for the eligible patients (P = 0.0084). At a median of 8 years follow-up, 4-year progression-free survival for all patients was 56% in the CHOP arm and 40% in the CIOP arm (P = 0.0096). Overall survival for all patients was 65% in the CHOP arm and 56% in the CIOP arm (P = 0.14). Results for eligible patients were comparable. CIOP containing idarubicin at a dose of 10 mg/m(2) is clearly inferior to standard CHOP.

Item Type:	Article
Authors (ICR Faculty only):	Cunningham, David
All Authors:	Burton, C., Smith, P., Vaughan-Hudson, G., Qian, W., Hoskin, P., Cunningham, D., Hancock, B., Linch, D.
Uncontrolled Keywords:	non-Hodgkin lymphoma; histologically aggressive; CHOP; CIOP; idarubicin Multidrug-resistance; malignant-lymphoma; cardiac toxicity; idarubicin; chemotherapy; adriamycin; expression; regimen; cancer
Research teams:	Clinical Units > Haemato-Oncology Unit
Depositing User:	EPrints Services
Date Deposited:	10 Aug 2007 20:53
Last Modified:	24 Apr 2015 09:39
URI:	http://publications.icr.ac.uk/id/eprint/2425

Actions (login required)

View Item